Skip to content
HomeJohnson & Johnson Statement on Outcome of Global Drug Facility Tender for Generic Forms of SIRTURO® 100mg (bedaquiline)

Johnson & Johnson Statement on Outcome of Global Drug Facility Tender for Generic Forms of SIRTURO® 100mg (bedaquiline)

Share Article
share to

The introduction of generic forms of SIRTURO® 100mg (bedaquiline), our medicine for multidrug-resistant tuberculosis (MDR-TB), in low-and middle-income countries is an example of the lifecycle for medicines. It is made possible by Johnson & Johnson’s investments in innovation on behalf of the patients we serve, and our continuing, collaborative and patient-focused efforts with Stop TB Partnership’s Global Drug Facility and many other partners.

Generic forms of SIRTURO®100mg will not solve MDR-TB. Underdiagnosis remains the most significant barrier to treatment, with nearly two-thirds of the 450,000 people who develop MDR-TB each year not diagnosed and enrolled on treatment. We have dedicated significant resources to overcome this challenge and we must all get behind it and work together if we are to save lives and achieve the global goal of ending TB.

You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.